Rein Therapeutics’ LTI-2355 peptide shows therapuetic potential in study

Rein Therapeutics (RNTX) announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis – IPF – and Post-Acute Sequelae of COVID Fibrosis – PASC-F – in the peer-reviewed journal, Biomedicines. The manuscript describes the effects of caveolin scaffolding domain peptide LTI-2355 on the immune and synthetic properties of human lung-derived macrophages and other myeloid cells isolated from lung explant tissue of donor lungs, as well as IPF and PASC-F lung explant tissue. LTI-2355 is a CSD peptide with anti-fibrotic properties that has been used in several preclinical models of fibrosis. In the present study, LTI-2355 improved the phagocytic activity of both IPF and PASC-F myeloid cells compared with control peptide-treated cells, and this improvement coincided with decreased pro-inflammatory and pro-fibrotic synthetic activity of the diseased cells.